An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 323 participants.
Also called NCT07543120
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 323 participants
- Sponsor
- Registry
-
NCT07543120
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Japan, Singapore
- Registry status
- Recruiting
Technical summary
Registry record NCT07543120. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-07 (actual); primary completion 2031-05-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
- Condition
- Hypertension (HTN)
- Intervention (Drug)
- QCZ484
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07543120- Content hash
5801eef701a0ac4edb21550bc0874b03115afc160158bbcb295585f6bc2fabc2